Related references
Note: Only part of the references are listed.Combination therapy in inflammatory bowel disease: Current evidence and perspectives
Cong Dai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2023)
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine et al.
JOURNAL OF CROHNS & COLITIS (2022)
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study
Daniela Pugliese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
Alfredo Papa et al.
BIOMEDICINES (2022)
Effect of IBD medications on COVID-19 outcomes: results from an international registry
Ryan C. Ungaro et al.
GUT (2021)
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
Brian Bressler et al.
JOURNAL OF CROHNS & COLITIS (2021)
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
Manasi Agrawal et al.
JOURNAL OF CROHNS & COLITIS (2021)
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy
Sandro Ardizzone et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme
Silvio Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
Hadrien Alric et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases
Jacob J. Rozich et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
COVID-19 and immunomodulation in IBD
Markus F. Neurath
GUT (2020)
Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research
Tristan Townsend et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Circulating exosomes express α4β7 integrin and compete with CD4+T cells for the binding to Vedolizumab
Rossana Domenis et al.
PLOS ONE (2020)
Preventing COVID-19-induced pneumonia with anticytokine therapy
Giovanni Monteleone et al.
LANCET RHEUMATOLOGY (2020)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience
Uri Kopylov et al.
DIGESTIVE AND LIVER DISEASE (2019)
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study
Aurelien Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers
Antonio Tursi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Neeraj Narula et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study
Marco Vincenzo Lenti et al.
DIGESTIVE AND LIVER DISEASE (2018)
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2018)
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Stefan Schreiber et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Maria Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres
Mark A. Samaan et al.
FRONTLINE GASTROENTEROLOGY (2017)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
Stefanos Bonovas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
Leon P. McLean et al.
IMMUNOTHERAPY (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical implications of mucosal healing for the management of IBD
Guillaume Pineton de Chambrun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Predicting the Crohn's disease activity index from the Harvey-Bradshaw index
WR Best
INFLAMMATORY BOWEL DISEASES (2006)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
EV Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Share Paper
